3.78% 0.0091

Dopo l'orario di chiusura: .25

Scisparc Ltd (SPRC)

Scisparc Ltd Borsa (SPRC) Ultime notizie

Scisparc Ltd (SPRC)

Scisparc Ltd Borsa (SPRC) Ultime notizie

SciSparc Ltd. Proposes Reverse Stock Split - TipRanks

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN

SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada

SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com

SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Australia

SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com India

SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks

SciSparc signs LOI to sell entire ownership in MitoCareX - MSN

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - StockTitan

Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News

Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World

Smartgroup Announces Major Shareholding Changes - TipRanks

Science Group PLC Executes Share Buyback - TipRanks

Site Group Plans Massive New Share Issue - TipRanks

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat

CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks

Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle

SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts

Clearmind, SciSparc slide amid weight-loss study results - MSN

FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter

UBS Cuts Stake in Spirent Communications - TipRanks

SThree maintains expectations amid tough market conditions. - Research the market

UK recruiter SThree falls on lower Q3 net fee - XM

SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK

Science Group PLC Announces Share Buyback - TipRanks

SThree plc Navigates Market Headwinds in Q3 - TipRanks

SThree Net Fees Fall Amid Challenging Environment - MarketWatch

Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World

Market Watch: SciSparc Ltd (SPRC)’s Noteworthy Drop, Closing at 0.26 - The Dwinnex

Barclays Ups Stake in Spirent Communications - TipRanks

FDA greenlights SciSparc's phase IIb trial for Tourette Syndrome - Investing.com

Are SciSparc Ltd’shares a good deal? - US Post News

SciSparc Advances Tourette Syndrome Drug Trial - TipRanks

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewswire

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - Marketscreener.com

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - StockTitan

Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Sprout Social, Inc. (SPT): Short Seller Sentiment is Bearish on This AI Stock Under $50 - Insider Monkey

Canaccord Genuity stays at 'speculative buy' on Spirent Communications - ShareCast

Shipping Corporation of India (NSE:SCI) stock performs better than its underlying earnings growth over last five years - Simply Wall St

Spirit Tech’s New Securities Hit ASX - TipRanks

Brighton Jones LLC Boosts Stock Position in Sprout Social, Inc. (NASDAQ:SPT) - Defense World

Acadian Asset Management LLC Invests $27,000 in SPAR Group, Inc. (NASDAQ:SGRP) - Defense World

Strix Group First Half 2024 Earnings: UK£0.023 loss per share (vs UK£0.018 profit in 1H 2023) - Simply Wall St

Sappi appoints Graeme Wild as CEO of its South African operations - IOL

Inspire Investing LLC Has $1.19 Million Position in SMART Global Holdings, Inc. (NASDAQ:SGH) - Defense World

SPRC stock touches 52-week low at $0.25 amid sharp annual decline - Investing.com

ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00 - MarketBeat

Spruce Biosciences Inc (SPRB) expanding its growth trajectory ahead - SETE News

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

ARS Pharmaceuticals Inc [SPRY] Records 50-Day SMA of $11.83 - Knox Daily

SIGA Technologies (NASDAQ:SIGA) Trading Up 6.8% - MarketBeat

Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Canada

Safire Group Raises $8M in Financing - FinSMEs

UBS Group AG Increases Stake in Spirent Communications - TipRanks

Spruce Biosciences Inc’s results are impressive - US Post News

SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Australia

Atlantic Sapphire Announces Major Rights Issue - TipRanks

Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex

SciSparc advances phase IIb trial for Tourette Syndrome treatment - Investing.com India

SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Canada

SkinBioTherapeutics Gears Up for Market Launch - TipRanks

Strix Group (LON:KETL) Stock Price Down 5.5% - Defense World

SPRCSciSparc Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

SciSparc advances phase IIb trial for Tourette Syndrome treatment - Investing.com

SciSparc Takes Major Step Forward with IND Application - GlobeNewswire

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - Marketscreener.com

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - StockTitan

Stryker Stock Declines Despite Completion of care.ai Acquisition - Yahoo Finance

Simile a SPRC